What it is
GHK-Cu / BPC-157 is a vendor name for two peptides in one vial: GHK-Cu, a copper-binding tripeptide, and BPC-157, a synthetic fragment derived from a protein found in gastric juice. It is the same pair that makes up two thirds of GLOW, sold here without the TB-500. It has no INN, no CAS number of its own and no approved indication anywhere.
The name is easy to confuse with its relatives. Wolverine is BPC-157 and TB-500, no GHK-Cu at all. GLOW is this pair plus TB-500. KLOW is GLOW plus KPV. A product sold under any of the four names may in practice be any of the four compositions, and the name alone does not tell a buyer which.
What is actually in the vial
The most commonly described split is GHK-Cu 50 mg to BPC-157 10 mg, a 5:1 ratio by mass, usually reconstituted in 3 mL of bacteriostatic water. That GHK-Cu figure matches the GHK-Cu content of the GLOW and KLOW vials already on this site, which suggests 50 mg is a round-number convention for the GHK-Cu component across several blend products rather than something specific to the two-peptide version. As with every other blend on this site, no independent, dated survey of multiple vendor listings for this specific two-peptide product was carried out for this entry, and no dose-ranging study has ever compared this ratio against any other.
The copper question
Putting a copper-binding peptide in the same vial as another peptide raises an obvious question: does the copper do anything to the other molecule? GHK-Cu holds its copper ion tightly enough to strip it from albumin’s own transport site, and free or loosely bound copper is a classical catalyst for oxidative damage to proteins, acting mainly on methionine, cysteine, tryptophan, histidine and tyrosine side chains.
BPC-157’s published sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Reading that off, it contains none of the five residues copper oxidation chemistry is best known to target. That is a genuine, checkable point in favour of this specific pairing being less chemically fragile than a copper peptide mixed with a methionine- or cysteine-bearing molecule would be. It is not the same as a stability study. Nobody has actually tested whether copper transfers, whether it accelerates degradation through some other pathway, or whether either peptide is stable in the other’s presence over the weeks a reconstituted vial sits in a refrigerator, and no such study was located for this entry.
What is known about the combination
No study, animal or human, that tested GHK-Cu and BPC-157 administered together was located for this entry. Two 2026 scoping and narrative reviews in The American Journal of Sports Medicine cover both peptides, among others, for musculoskeletal and sports-medicine use, but each reviews the two compounds on their own literatures; neither describes a study in which the two were given together, and neither uses the word combination or blend for this pair.
No registered trial of this combination exists on ClinicalTrials.gov. A claim that circulates in product-facing material, that adding BPC-157 reduces the injection-site pain some people report with GHK-Cu, was located in enthusiast and vendor writing reviewed for this entry, framed there as a hypothesis based on BPC-157’s general anti-inflammatory reputation rather than as a tested finding. No study measuring injection-site reaction with and without BPC-157 present was found, so that claim is reported here only as something that circulates, not as something established.
What the component evidence actually says
Both peptides have their own entries on this site, and both are worth reading before this blend makes sense. In brief:
- BPC-157 has no identified receptor after roughly 230 published papers, about 77 percent of which come from one laboratory in Zagreb. Its three published human reports come from one clinic in Florida, thirty-one patients in total, with no control group.
- GHK-Cu is the compound on this site where circulating dose and documented practice are furthest apart: topical figures used in product range from 0.05 to 3 percent, a sixty-fold spread, and its flagship TGF-beta mechanism is contested in the primary literature rather than settled.
Putting two compounds in a vial does not combine their evidence bases. It combines their separate unknowns and adds a question about their interaction that nobody has studied.
What is not known
Whether copper redistributes between the peptide and its surroundings in a mixed solution, and whether either component degrades faster because of it. Whether the 5:1 ratio has any pharmacological basis, or is a convenient round number carried over from the three- and four-peptide blends that share the same GHK-Cu figure. Whether combining the two changes injection-site reactions in either direction; the claim that it helps is reported here as circulating, not demonstrated. Whether the combination does anything a single component would not, in any measured outcome, in any species. Everything already unknown about each component alone, which on the BPC-157 side includes carcinogenicity and human pharmacokinetics, and on the GHK-Cu side includes the direction of its central signalling mechanism.
Regulatory status
Neither component is an approved drug. BPC-157 was recommended for the 503A compounding list by the FDA Pharmacy Compounding Advisory Committee in July 2026, against FDA staff’s own recommendation, and the agency has not acted on that recommendation. GHK-Cu’s regulatory attention runs through a different channel: it has drawn scrutiny from the Cosmetic Ingredient Review panel over the concentrations used in topical products, not from an FDA drug-compounding action, and no FDA warning letter or advisory-committee vote specific to GHK-Cu as an injectable was located for this entry.